# SSGXVIII/AIO (adjuvant imatinib in GIST)

Source: https://onco.cc/trials/ssgxviii/  
OnCo record `ssgxviii` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In SSGXVIII/AIO, three years of imatinib after surgery, rather than one, improved survival in high-risk GIST.

## Summary

SSGXVIII/AIO, trial NCT00116935 sponsored by the Scandinavian Sarcoma Group and the German AIO and published in JAMA in 2012, showed that three years of adjuvant imatinib after surgery, rather than one, improves recurrence-free and overall survival in high-risk gastrointestinal stromal tumour. It randomised 400 patients and met its primary recurrence-free survival endpoint at five years with a survival benefit that held at ten years. OnCo links it to sarcomas and GIST, KIT as a target and imatinib. Trials of five to six years of imatinib, SSG XXII and IMADGIST, suggest further recurrence-free benefit, and how long adjuvant imatinib should continue is the open question.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT00116935
- Phase: 3
- Setting: High-risk resected GIST: adjuvant imatinib 3 years vs 1 year
- Sponsor: Scandinavian Sarcoma Group / AIO
- Enrolled: 400
- Result: RFS HR 0.46; OS HR 0.45 (5 years).
- Outcomes: Recurrence-free survival at 5 years: Imatinib 3 years 65.6% vs Imatinib 1 year 47.9%, HR 0.46; Overall survival at 5 years: Imatinib 3 years 92% vs Imatinib 1 year 81.7%, HR 0.45

## Sources

- ClinicalTrials.gov NCT00116935: https://clinicaltrials.gov/study/NCT00116935

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KIT](https://onco.cc/targets/kit/)
- drugs: [Imatinib](https://onco.cc/drugs/imatinib/)
- companies: [AIO (Arbeitsgemeinschaft Internistische Onkologie)](https://onco.cc/companies/aio/), [Scandinavian Sarcoma Group](https://onco.cc/companies/scandinavian-sarcoma-group/)

---
JSON: https://onco.cc/api/v1/entities/ssgxviii.json